Inventiva S.A (IVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inventiva S.A (IVA) has a cash flow conversion efficiency ratio of 1.796x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-51.24 Million ≈ $-59.90 Million USD) by net assets (€-28.52 Million ≈ $-33.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IVA equity to assets ratio to measure how much of total assets are equity-financed.
Inventiva S.A - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Inventiva S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Inventiva S.A long-term investment intensity to see how much of total assets are deployed in long-term investments.
Inventiva S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inventiva S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen JingQuanHua Electronics Co Ltd
SHE:002885
|
0.013x |
|
Guanglian Aviation Industry Co Ltd
SHE:300900
|
-0.015x |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
N/A |
|
Jiangsu Wuyang Parking Industry Group Co Ltd
SHE:300420
|
0.010x |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
0.024x |
|
United Fire Group Inc
NASDAQ:UFCS
|
0.068x |
|
Sheela Foam Limited
NSE:SFL
|
0.038x |
|
Centerspace
NYSE:CSR
|
0.026x |
Annual Cash Flow Conversion Efficiency for Inventiva S.A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Inventiva S.A from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Inventiva S.A worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
€-104.88 Million ≈ $-122.62 Million |
3.677x | +356.39% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
€-85.93 Million ≈ $-100.46 Million |
0.806x | -68.38% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
€-81.61 Million ≈ $-95.42 Million |
2.548x | +357.90% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
€-44.93 Million ≈ $-52.53 Million |
-0.988x | -84.33% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
€-47.63 Million ≈ $-55.68 Million |
-0.536x | -94.85% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
€-30.59 Million ≈ $-35.76 Million |
-0.275x | +59.92% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
€-28.40 Million ≈ $-33.21 Million |
-0.686x | -23.57% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
€-34.21 Million ≈ $-39.99 Million |
-0.555x | -109.07% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
€-17.00 Million ≈ $-19.88 Million |
-0.266x | +36.15% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
€-14.86 Million ≈ $-17.37 Million |
-0.416x | -27.24% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
€-13.98 Million ≈ $-16.35 Million |
-0.327x | -13.88% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
€-14.79 Million ≈ $-17.29 Million |
-0.287x | -5.83% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
€-16.01 Million ≈ $-18.72 Million |
-0.271x | -- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more